GENE ONLINE|News &
Opinion
Blog

2021-06-24| ChinaR&D

China’s Legend Biotech to Build a CAR-T Therapy Production Site in Belgium

by Tyler Chen
Share To

Fresh off completing a rolling submission for ciltacabtagene autoleucel (cilta-cel), a CAR-T therapy co-developed with Janssen, China’s Legend Biotech, has announced plans to establish a manufacturing facility in Belgium to boost the production of cilta-cel once it’s FDA approved.

 

Third Plant for Legend Biotech, a First in Europe

The Belgium facility is going to be the first plant in Europe and the third for Legend Biotech on top of the two in Nanjing, China, and New Jersey, US. For now, details of the plant remain unclear, but the site is expected to go into operation by 2023 and focus on manufacturing cell therapy products.

Also, it would put Legend Biotech in a better position to tap the local talent pool and support global supply as soon as cilta-cel gets approved.

 

Collaboration with Janssen

Janssen started working with Legend Biotech on developing CAR-T therapy at the end of 2017. The drug is developed for patients with relapsed/refractory multiple myeloma. It received a Breakthrough Therapy Designation (BTD) in the US in December 2019 and also got priority review in May 2021, meaning the FDA will make the decision by November 29th. What’s more, it’s the first CAR-T therapy accepted for review by the China Food and Drug Administration (CFDA).

 

Approved CAR-T Therapies

If approved, cilta-cel will be the second CAR-T therapy to treat those with relapsed/refractory multiple myeloma as BMS and bluebird bio won the race in March with Abecma, entering the market as the fifth CAR-T therapy and the first for the indication.

Currently, the US FDA has approved five CAR-T therapies, including Abecma and Breyanzi by BMS, Tecartus and Yescarta by Gilead, and Kymriah by Novartis.

Related Article: From Great Challenges to Great Opportunities: An Outlook on US-China Biotech Relationships

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Walmart To Settle Opioid Lawsuits with $3.1 Billion, U.S. Government Mulls OTC Naloxone
2022-11-15
Moderna To Collaborate With Harbour BioMed On Nucleic Acid-Based Cancer Therapies
2022-11-14
The FDA Expands Use for Gilead Science’s HBV Treatment
2022-11-02
LATEST
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
Scientists Identify New Genetic Variant Related to Obesity
2022-12-01
Micronbrane Medical Aspires to Further Clinical Collaboration Following the Successful Series A Funding
2022-12-01
FDA Revokes Authorization Of Eli Lilly’s COVID-19 Antibody
2022-12-01
Eisai Unveils Lecanemab Data Following Reports of Second Alzheimer’s Patient Death
2022-11-30
New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio
2022-11-30
Gland Pharma Dispels Rumors Of Fosun Sale, Acquires Cenexi In Separate Development
2022-11-30
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!